Cost-effectiveness of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer

Cost-effectiveness of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer

BackgroundThe efficiency and safety of sacituzumab govitecan (SG) for the therapy of hormone receptor-positive (HR+)/human epidermal receptor 2-negative (HER2-) metastatic breast cancer (BC) has been demonstrated. The aim of this study is to evaluate its cost-effectiveness on HR+/HER2- metastatic BC...

Full description

Bibliographic Details
Main Authors:	Demin Shi, Yan Li, Xueyan Liang, Lingyuan Chen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-05-01
Series:	Frontiers in Oncology
Subjects:	cost-effectiveness sacituzumab govitecan breast cancer hormone receptor-positive human epidermal receptor 2-negative partitioned survival model
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1162360/full

Similar Items

Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer
by: Yitian Lang, et al.
Published: (2023-04-01)

Sacituzumab-govitecan-induced severe acute tubulointerstitial nephritis requiring hemodialysis
by: Geneva Guarin, et al.
Published: (2024-11-01)

Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US
by: Jigang Chen, et al.
Published: (2021-10-01)

Sacituzumab govitecan expands its therapeutic spectrum among breast cancer subtypes
by: Semir Vranic
Published: (2023-03-01)

Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer
by: Jiao Xie, et al.
Published: (2023-06-01)

Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis
by: Roberta Caputo, et al.
Published: (2024-03-01)

Efficacy and Safety of Sacituzumab Govitecan on Advanced HER2-negative Breast Cancer: A Meta-analysis
by: ZHANG Qian, et al.
Published: (2022-04-01)

Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer
by: Mita Manna, et al.
Published: (2024-09-01)

Cost-effectiveness of sacituzumab govitecan versus single-agent chemotherapy for metastatic triple-negative breast cancer: a trial-based analysis
by: Yilai Wu, et al.
Published: (2024-04-01)

Sacituzumab govitecan and radiotherapy in metastatic, triple-negative, and BRCA-mutant breast cancer patient with active brain metastases: A case report
by: Pierluigi di Mauro, et al.
Published: (2023-02-01)

A New Kid on the Block: Sacituzumab Govitecan for the Treatment of Breast Cancer and Other Solid Tumors
by: Giuliana Pavone, et al.
Published: (2021-12-01)

Assessing real-world safety concerns of Sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system
by: Xiujuan Gui, et al.
Published: (2023-10-01)

Sacituzumab govitecan response in extensive leptomeningeal carcinomatosis from triple-negative breast cancer: a case report
by: Jesús Yaringaño, et al.
Published: (2024-08-01)

Sacituzumab Govitecan for Second and Subsequent Line Palliative Treatment of Patients with Triple-Negative Breast Cancer: A Polish Real-World Multicenter Cohort Study
by: Miroslawa Püsküllüoğlu, et al.
Published: (2024-09-01)

Response to trastuzumab deruxtecan in a patient with HER2-low metastatic breast cancer previously treated with sacituzumab govitecan
by: Stefano Testa, et al.
Published: (2023-09-01)

Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine
by: Saif Khan, et al.
Published: (2024-12-01)

Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back
by: Valentina Rossi, et al.
Published: (2024-08-01)

Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database
by: Wensheng Liu, et al.
Published: (2023-11-01)

Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer
by: Michelle Greenman, et al.
Published: (2024-08-01)

Safety profile of sacituzumab govitecan in patients with breast cancer: A systematic review and meta-analysis
by: Maria Inez Dacoregio, et al.
Published: (2025-02-01)

Preclinical evidence for the use of anti‐Trop‐2 antibody‐drug conjugate Sacituzumab govitecan in cerebral metastasized castration‐resistant prostate cancer
by: Richard Weiten, et al.
Published: (2024-06-01)

Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo
by: Emanuele Perrone, et al.
Published: (2020-03-01)

UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan
by: Megan H. Wong, et al.
Published: (2024-08-01)

Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer
by: Emanuele Perrone, et al.
Published: (2020-02-01)

Cost-benefit evaluation of advanced therapy lines in metastatic triple-negative breast cancer in Germany
by: Amelie Wickmann, et al.
Published: (2024-03-01)

Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium
by: Jiazheng Yu, et al.
Published: (2023-07-01)

Major pathologic response and long-term clinical benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after neoadjuvant chemotherapy
by: Lei Ji, et al.
Published: (2024-12-01)

Safety and Efficacy of Everolimus Plus Exemestane in Postmenopausal Women with Treatment-refractory Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer: Analysis from EVEREXES Taiwan Subset
by: Yuan-Ching Chang, et al.
Published: (2023-07-01)

Hormonal Receptors, Human Epidermal Growth Factor Receptor-2 and Triple Negative Immunohistochemical Typing in Women with Breast Cancer in Kampala, Uganda
by: Mlole AT, et al.
Published: (2020-11-01)

Best of the year: Advanced breast cancer in 2023
by: Ilana Schlam, et al.
Published: (2024-04-01)

Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy
by: Jae Ho Jeong, et al.
Published: (2022-12-01)

Therapy for Hormone Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer Following Treatment Progression via CDK4/6 Inhibitors: A Literature Review
by: Ye M, et al.
Published: (2024-04-01)

Analysis of multimodal ultrasonic characteristics in breast cancer with human epidermal growth factor receptor 2 positive under different expression status of hormone receptor2
by: CANG Qing, YIN Liang, ZHANG Aihua, YE Xinhua
Published: (2024-10-01)

A multicenter study on TROP2 as a potential targeted therapy for extramammary Paget disease in Japan
by: Takamichi Ito, et al.
Published: (2025-01-01)

Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions
by: Yujun Tong, et al.
Published: (2024-11-01)

Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) metastatic breast cancer: A review
by: Ran Ran, et al.
Published: (2022-12-01)

Prognostic value of localization of epidermal growth factor receptor in lung adenocarcinoma
by: Jinn-Li Wang, et al.
Published: (2018-06-01)

The Real-world Experiences of Abemaciclib for Estrogen Receptor-positive Human Epidermal Growth Factor Receptor-negative-2 Metastatic Breast Cancer – Sharing from a Single Institute in Southern Taiwan
by: Jui-Hung Tsai, et al.
Published: (2024-06-01)

Glycoprotein G-protein Coupled Receptors in Disease: Luteinizing Hormone Receptors and Follicle Stimulating Hormone Receptors
by: Duaa Althumairy, et al.
Published: (2020-09-01)

New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients
by: Jun Yamamura, et al.
Published: (2021-04-01)